Long-form, plain-English guides that translate clinical research and real user experiences into clear answers.
In two years, GLP-1s picked up FDA approvals for heart disease, kidney disease, sleep apnea, and liver disease. Here is what the trials found, and the fine print on who those benefits are for.
Read the guide →The trials measure people who stay on the drug. In the real world, most people quit within a year. Here is what the data shows about how many stop, why (cost leads), who stays on, and what happens after.
Read the guide →The fear that a GLP-1 is cheating, or the easy way out, is one of the biggest reasons people hesitate and stay quiet. Here is what the research and the biology say.
Read the guide →The clinical evidence on weight regain after stopping Wegovy, Ozempic, or Zepbound: how much comes back, how fast, and what the withdrawal trials (STEP 1, STEP 4, SURMOUNT-4) really found.
Read the guide →Terrified of the first GLP-1 shot? You're not alone, and you're not being dramatic. A reassuring, step-by-step walkthrough, plus the exact tactics people who panicked over their first injection used to get through it.
Read the guide →A calm, sourced walkthrough of weeks 1–4 on Wegovy or Zepbound: the starter dose, when side effects show up, what the scale will (and won't) do, and when to call your doctor.
Read the guide →One plain-English email a month: new study findings, price changes, and safety updates. No spam, ever.